Bevacizumab (trade name Avastin, Genentech/Roche)

Bevacizumab (trade name Avastin, Genentech/Roche) is a drug that blocks angiogenesis, the growth of new blood vessels. It is commonly used to treat various cancers, including colorectal, lung, breast, kidney, and glioblastomas.

Bevacizumab is a humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A). VEGF-A is a chemical signal that stimulates angiogenesis in a variety of diseases, especially in cancer. Bevacizumab was the first clinically available angiogenesis inhibitor in the United States.

Bevacizumab was approved by the U.S. Food and Drug Administration (FDA) for certain metastatic cancers. It received its first approval in 2004 for combination use with standard chemotherapy for metastatic colon cancer. While at one point approved for breast cancer by the FDA, the approval was revoked on 18 November 2011.

Read more: http://en.wikipedia.org/wiki/Bevacizumab

If you or a loved one has suffered any of the above serious Avastin side effects, or other serious side effects from Avastin, please contact your doctor immediately.  You are also urged to contact the law firm of Audet & Partners, LLP to protect your legal rights.  You may call us toll-free at 800.965.1461, or you may use this secure form.